Drug intelligence / Profile preview

TMH001

Development stage: Preclinical
Lead developer: Pacific GeneTech
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

TMH001 is an inactivated oral vaccine developed by Pacific GeneTech from its "Aegis" vaccine platform. It is designed for the control of coccidiosis in poultry, providing a safer alternative to traditional antibiotics and live vaccines. The vaccine technology originated from research conducted at the University of Arkansas Poultry Health Laboratory with support from the U.S. Department of Agriculture. Kemin Industries, through its subsidiary Kemin Biologics, holds exclusive global licensing rights for the development, registration, and commercialization of TMH001.

Beyond the preview

Go deeper on TMH001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMH001.

Explore the full profile